| ［1］ |
中国医师协会皮肤科医师分会科学委员会, 中国医师协会皮肤科医师分会变态反应性疾病专业委员会, 中国"手部湿疹科研协作组". 中国手部湿疹诊疗专家共识（2021版）［J］. 中华皮肤科杂志, 2021,54（1）:19⁃26. doi: 10.35541/cjd.20200281.
|
| ［2］ |
Tauber M, Lourari S, Bérard E, et al. Positive change in hand care habits using therapeutic patient education in chronic hand eczema［J］. Contact Dermatitis, 2020,82（1）:10⁃17. doi: 10.1111/cod.13390.
|
| ［3］ |
Rademaker M, Armour K, Baker C, et al. Management of chronic hand and foot eczema. An Australia/New Zealand clinical narrative［J］. Australas J Dermatol, 2021,62（1）:17⁃26. doi: 10.1111/ajd.13418.
|
| ［4］ |
Wang X, Xu W, Chen Y, et al. Staphylococcus aureus colonization and chronic hand eczema: a multicenter clinical trial［J］. Arch Dermatol Res, 2019,311（7）:513⁃518. doi: 10.1007/s00403⁃019⁃01924⁃x.
|
| ［5］ |
Dubin C, Del Duca E, Guttman⁃Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges［J］. Ther Clin Risk Manag, 2020,16:1319⁃1332. doi: 10.2147/TCRM.S292504.
|
| ［6］ |
Worm M, Thyssen JP, Schliemann S, et al. The pan⁃JAK inhibitor delgocitinib in a cream formulation demonstrates dose⁃response in chronic hand eczema in a 16⁃week randomised phase 2b trial［J］. Br J Dermatol, 2022,doi: 10.1111/bjd.21037.
|
| ［7］ |
Fujita K, Yagi M, Moriwaki S, et al. A phase 2b, randomized, double⁃blind, multicenter, vehicle⁃controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild⁃to⁃moderate atopic dermatitis［J］. J Dermatol, 2021,48（11）:1640⁃1651. doi: 10.1111/1346⁃8138.16120.
|
| ［8］ |
Kahn JS, Grossman⁃Kranseler JS, Zancanaro P, et al. Topical crisaborole in the treatment of atopic hand dermatitis: a retrospective chart review［J］. Dermatitis, 2021,32（6）:e141⁃e143. doi: 10.1097/DER.0000000000000793.
|
| ［9］ |
Trong HN, Tat TN, Anh T, et al. Efficacy of adding oral simvastatin to topical therapy for treatment of psoriasis: the Vietnamese experience［J］. Open Access Maced J Med Sci, 2019,7（2）:237⁃242. doi: 10.3889/oamjms.2019.060.
|
| ［10］ |
Mehrpooya M, Ghaed⁃Amini F, Firozian F, et al. Beneficial effects of adding topical atorvastatin 5% cream to topical betamethasone 1% ointment on chronic hand eczema［J］. Arch Iran Med, 2020,23（9）:605⁃613. doi: 10.34172/aim.2020.71.
|
| ［11］ |
Reich A, Lopez Estebaranz JL, Bahadoran P, et al. A spray containing extracts of oat plantlets and Uncaria tomentosa relieves pain associated with chronic inflammatory skin diseases and dermatological procedures［J］. J Eur Acad Dermatol Venereol, 2020,34 Suppl 2:3⁃11. doi: 10.1111/jdv.16428.
|
| ［12］ |
Khademi A, Mansuri P, Pahlevan D, et al. Efficacy of pumpkin ointment in treatment of chronic hand eczema: a randomized, active⁃controlled, double blind clinical trial［J］. Iran J Public Health, 2020,49（7）:1339⁃1347. doi: 10.18502/ijph.v49i7.3588.
|
| ［13］ |
Pawar M. Topical timolol in chronic, recalcitrant fissures and erosions of hand eczema［J］. J Am Acad Dermatol, 2021,84（3）:e125⁃e126. doi: 10.1016/j.jaad.2020.04.070.
|
| ［14］ |
Juntongjin P, Chunhakham P. Synergistic effects of the 308⁃nm excimer light and topical calcipotriol for the treatment of chronic hand eczema: a randomized controlled study［J］. Dermatology, 2021,237（1）:31⁃38. doi: 10.1159/000505539.
|
| ［15］ |
Kremer N, Sherman S, Lapidoth M, et al. Self⁃administered daylight⁃activated photodynamic therapy for the treatment of hand eczema: a prospective proof⁃of⁃concept study［J］. Dermatol Ther, 2020,33（6）:e14329. doi: 10.1111/dth.14329.
|
| ［16］ |
Waked IS, Ibrahim ZM. Beneficial effects of paraffin bath therapy as additional treatment of chronic hand eczema: a randomized, single⁃blind, active⁃controlled, parallel⁃group study［J］. J Altern Complement Med, 2020,26（12）:1144⁃1150. doi: 10.1089/acm.2020.0356.
|
| ［17］ |
Seol JE, Kim JU, Hong SM, et al. Alitretinoin compliance in patients with chronic hand eczema［J］. Ann Dermatol, 2021,33（1）:46⁃51. doi: 10.5021/ad.2021.33.1.46.
|
| ［18］ |
Poizeau F, Balusson F, Jonville⁃Béra AP, et al. The cardiovascular safety of oral alitretinoin: a population⁃based cohort study involving 19 513 patients exposed to oral alitretinoin［J］. Br J Dermatol, 2021,185（4）:764⁃771. doi: 10.1111/bjd.20069.
|
| ［19］ |
Waldman RA, DeWane ME, Sloan B, et al. Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients［J］. J Am Acad Dermatol, 2020,82（5）:1251⁃1252. doi: 10.1016/j.jaad.2019.12.053.
|
| ［20］ |
Loman L, Diercks G, Schuttelaar M. Three cases of non⁃atopic hyperkeratotic hand eczema treated with dupilumab［J］. Contact Dermatitis, 2021,84（2）:124⁃127. doi: 10.1111/cod.13693.
|
| ［21］ |
Halling AS, Zachariae C, Thyssen JP. Severe treatment⁃resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab［J］. Contact Dermatitis, 2020,83（1）:37⁃38. doi: 10.1111/cod.13501.
|
| ［22］ |
Zhu GA, Honari G, Ko JM, et al. Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: a case report［J］. JAAD Case Rep, 2020,6（4）:296⁃298. doi: 10.1016/j.jdcr.2020.02.010.
|
| ［23］ |
Oosterhaven J, Voorberg AN, Romeijn G, et al. Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study［J］. J Dermatol, 2019,46（8）:680⁃685. doi: 10.1111/1346⁃8138.14982.
|
| ［24］ |
Singh R, Heron CE, Ghamrawi RI, et al. Emerging role of janus kinase inhibitors for the treatment of atopic dermatitis［J］. Immunotargets Ther, 2020,9:255⁃272. doi: 10.2147/ITT.S229667.
|
| ［25］ |
Rosenberg FM, Loman L, Schuttelaar M. Baricitinib treatment of severe chronic hand eczema: two case reports［J］. Contact Dermatitis, 2022. doi: 10.1111/cod.14039.
|
| ［26］ |
Navarro⁃Triviño FJ, Cuenca⁃Barrales C, Vega⁃Castillo JJ, et al. Chronic hand eczema and hepatogenic pruritus with good response to apremilast［J］. Dermatol Ther, 2019,32（3）:e12879. doi: 10.1111/dth.12879.
|
